Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

pharmareview.files.wordpress.com
from pharmareview.files.wordpress.com More from this publisher
02.06.2013 Views

(2003): D’Alessandro V+, Clin Ter 154(3), 207 Infections (16%) (2002): Poggi MM+, Int J Radiat Oncol Biol Phys 54(3), 670 Injection-site reactions (4%) Lymphedema (2000): Brandes A+, Anticancer Drugs 11, 15 (confined to areas of erysipeloid rash) Myalgia/Myositis/Myopathy/Myotoxicity (>10%) (2007): Huang YJ+, Chin Med J (Engl) 120(6), 458 (2002): Voorburg AM+, Lung Cancer 36(2), 203 (with cisplatin) (2001): Fogarty G+, Lung Cancer 33(2), 299 Nephrotoxicity (2007): Yamamoto A+, Pancreas 34(3), 378 (2001): Kintzel PE, Drug Saf 24(1), 19 Neurotoxicity (2007): Huang YJ+, Chin Med J (Engl) 120(6), 458 Pseudolymphoma (2001): Marucci G+, Br J Dermatol 145(4), 650 GEMFIBROZIL Trade names: Bolutol; Decrelip; Fibrocit; Gemlipid; Gen-Fibro; Gevilon Uno; Jezil; Lipur; Lopid (Pfizer); Nu-Gemfibrozil Indications: Hyperlipidemia Category: Fibrate; Lipid regulator Half-life: 1.5 hours Clinically important, potentially hazardous interactions with: atorvastatin, bexarotene, cyclosporine, dicumarol, ezetimibe, fluvastatin, interferon alfa, lovastatin, nicotinic acid, pioglitazone, pravastatin, repaglinide, rosuvastatin, roxithromycin, simvastatin, statins, warfarin Reactions Skin Abscess Acanthosis nigricans Angioedema Basal cell carcinoma Dermatitis (0.4%) (1988): Todd PA+, Drugs 36, 314 Dermatomyositis (

250 GEMFIBROZIL (1995): Abdul-Ghaffar NU+, J Clin Gastroenterol 21(4), 340 (with lovastatin) (1993): Knoll RW+, Conn Med 57(9), 593 (with lovastatin) (1991): Magarian GJ+, Arch Intern Med 151(9), 1873 (1990): JAMA 264(23), 2991 (with lovastatin) (1990): Marais GE+, AnnInternMed112(3), 228 (with lovastatin) (1990): Pierce LR+, JAMA 264(1), 71 (with lovastatin) GEMIFLOXACIN Synonyms: DW286; LA 20304a; SB-265805 Trade name: Factive Indications: Infections due to various microorganisms Category: Antibiotic, quinolone Half-life: 4–12 hours Clinically important, potentially hazardous interactions with: None Reactions Skin Angioedema Dermatitis (

250 GEMFIBROZIL<br />

(1995): Abdul-Ghaffar NU+, J Clin Gastroenterol 21(4), 340<br />

(with lovastatin)<br />

(1993): Knoll RW+, Conn Med 57(9), 593 (with lovastatin)<br />

(1991): Magarian GJ+, Arch Intern Med 151(9), 1873<br />

(1990): JAMA 264(23), 2991 (with lovastatin)<br />

(1990): Marais GE+, AnnInternMed112(3), 228 (with<br />

lovastatin)<br />

(1990): Pierce LR+, JAMA 264(1), 71 (with lovastatin)<br />

GEMIFLOXACIN<br />

Synonyms: DW286; LA 20304a; SB-265805<br />

Trade name: Factive<br />

Indications: Infections due to various microorganisms<br />

Category: Antibiotic, quinolone<br />

Half-life: 4–12 hours<br />

Clinically important, potentially hazardous interactions<br />

with: None<br />

Reactions<br />

Skin<br />

Angioedema<br />

Dermatitis (

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!